Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria.

Trial Profile

Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2011

At a glance

  • Drugs Pemetrexed (Primary)
  • Indications CNS cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Planned end date changed from 1 Oct 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
    • 23 Oct 2008 Actual start date (Oct 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top